Fuentenebro 1989.

Methods	Randomisation: implied randomisation. Blinding: double‐blind. Duration: 2 weeks. Design: parallel. Location: not indicated. Setting: not indicated.
Participants	Diagnosis: schizophrenia (DSM‐III). N = 50. Gender: not indicated. Age: not indicated. History: duration stable: not indicated, duration of illness: not indicated, number of previous hospitalisations: not indicated, age at onset: not indicated, severity of illness: not indicated, baseline antipsychotic dose: not indicated.
Interventions	1. Haloperidol: fixed/flexible dose: not indicated, dose range: not indicated, mean dose: not indicated. Initial 5 mg injection, change to oral medication within the first 24 to 48 hours. N = not indicated. 2. Molindone: fixed/flexible dose: not indicated, dose range: not indicated, mean dose: not indicated. Initial 2 mg injection, change to oral medication within the first 24 to 48 hours. N = not indicated.
Outcomes	Unable to use: Global state general: Clinical Global Impression (CGI) (no raw data available). Mental state general: Brief Psychiatric Rating Scale (BPRS) (no total score available for both study groups, no SDs available).
Notes	The primary aim of the study was to evaluate the patient`s response to antipsychotic agents as predictor of treatment response.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	The trial authors did not explicitly mention a randomisation, but described a double‐blinding. Thus we implied that the study was randomised.
Allocation concealment (selection bias)	Unclear risk	No further details.
Blinding (performance bias and detection bias) (performance bias)	Unclear risk	“Double‐blind”. No further details.
Blinding (performance bias and detection bias) (detection bias)	Unclear risk	“Double‐blind”. No further details.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	With missing data of 10 of the 50 randomised participants (20%), the overall attrition was moderate. The analyses were based on completers‐only data, but due to the moderate drop‐out rate, the risk of bias might be considered as being unclear.
Selective reporting (reporting bias)	High risk	The outcome data were not fully addressed (no usable data and SDs for the BPRS; no raw data for the CGI). The numbers of participants randomised to each treatment group (haloperidol or molindone) were not indicated.
Other bias	Unclear risk	Insufficient information to assess whether an important risk of bias exists.